# Bortezomib Maintenance in High Risk DLBCL

> **NCT01965977** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 59 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01965977
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04-08
- **Primary completion:** 2018-10-30
- **Final completion:** 2021-10-30
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01965977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01965977, "Bortezomib Maintenance in High Risk DLBCL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01965977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*